At 8.7% CAGR, the North America Deep Brain Simulation Market is Projected to be worth US$ 549.78 million by 2030, says Business Market Insights

According to Business Market Insights research, the North America deep brain simulation market was valued at US$ 282.86 million in 2022 and is expected to reach US$ 549.78 million by 2030, registering a CAGR of 8.7% from 2022 to 2030. Technological advancements and approvals in deep brain stimulation and rising prevalence of neurological disorders are the critical factors attributed to the North America deep brain simulation market expansion.

Robotic implantation, multi-target stimulation, improved microelectrode designs, rechargeable pulse generators, and personalized, targeted programming are among the technological advancements in deep brain stimulation (DBS). Owing to these advancements, DBS devices show fewer side effects and improved efficacy and symptom relief in Parkinson's patients compared to traditional methods. Abbott's Infinity Deep Brain Stimulation System is a technologically advanced new DBS that helps the patients manage their symptoms. It is the first wireless iOS software DBS mobile platform that has offered efficient and personalized therapy management with reduced risk of side effects.

In addition, there is an increase in FDA approvals for deep brain stimulation (DBS) devices in clinical applications such as tremors, severe obsessive-compulsive disorder, and dystonia. For instance, in March 2020, NeuroPace, Inc. received approval from the US FDA for MRI labeling its RNA system. Therefore, technological advancements in DBS are expected to create opportunities for the global deep brain stimulation market during the forecast period.  

On the contrary, side effects associated with deep brain stimulation hurdles the growth of North America deep brain simulation market.

Based on product, the North America deep brain simulation market is segmented into single channel deep brain stimulator, dual channel deep brain stimulator, and software and accessories. The dual channel deep brain stimulator segment held 50.7% share of North America deep brain simulation market in 2023, amassing US$ 143.46 million. It is projected to garner US$ 300.78 million by 2030 to expand at 9.7% CAGR during 2022–2030.

Based on application, the North America deep brain simulation market is segmented into Parkinson’s disease, tremor, dystonia, epilepsy, Alzheimer’s disease, and others. The Parkinson’s disease segment held 62.6% share of North America deep brain simulation market in 2023, amassing US$ 182.12 million. It is projected to garner US$ 359.74 million by 2030 to expand at 8.9% CAGR during 2022–2030.

Based on end user, the North America deep brain simulation market is segmented into hospitals, neurology clinics, ambulatory surgical centers, and others. The hospitals segment held 55.3% share of North America deep brain simulation market in 2022, amassing US$ 156.37 million. It is projected to garner US$ 318.58 million by 2030 to expand at 9.3% CAGR during 2022–2030.  

Based on country, the North America deep brain simulation market is segmented into the US, Canada, Mexico. Our regional analysis states that the US captured 88.8% share of North America deep brain simulation market in 2022. It was assessed at US$ 251.12 million in 2022 and is likely to hit US$ 489.22 million by 2030, exhibiting a CAGR of 8.7% during 2022–2030.  

Key players operating in the North America deep brain simulation market report Abbott Laboratories, Boston Scientific Corp, Medtronic Plc, and Newronika SpA, among others.

Contact Us
Phone: +16467917070
Email Id: sales@businessmarketinsights.com